UCB Stock Other OTC
Stocks
UCBJF
BE0003739530
Pharmaceuticals
OTC Markets Traded| Market Cap | 43.7B 50.36B 40.92B 37.43B 70.67B 4,797B 71.59B 479B 188B 2,397B 189B 185B 7,977B | P/E 2026 * |
23.3x | P/E 2027 * | 18.9x |
|---|---|---|---|---|---|
| Enterprise Value | 43.93B 50.62B 41.13B 37.63B 71.03B 4,822B 71.96B 481B 189B 2,409B 190B 186B 8,019B | EV / Sales 2026 * |
5.08x | EV / Sales 2027 * | 4.31x |
| Free-Float |
61.59% | Yield 2026 * |
0.64% | Yield 2027 * | 0.66% |
Last Transcript: UCB
| 1 day | -0.39% |
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 67 | 01/01/2015 | |
Sandrine Dufour
DFI | Director of Finance/CFO | 60 | 01/07/2020 |
Alistair Henry
CTO | Chief Tech/Sci/R&D Officer | 59 | 01/05/2024 |
| Director | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 55 | 01/01/2012 | |
| Director/Board Member | 67 | 01/01/2015 | |
| Director/Board Member | 56 | 24/04/2014 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -0.39% | -.--% | - | - | 50.46B | |
| -0.30% | +3.76% | +38.00% | -1.12% | 76.75B | |
| -1.83% | +3.69% | +23.09% | +181.53% | 50.46B | |
| +1.54% | +2.37% | -6.31% | +23.71% | 48.5B | |
| +1.30% | +3.35% | -50.46% | -50.08% | 44.14B | |
| -1.13% | -1.93% | +57.66% | -24.82% | 30.53B | |
| -2.04% | -4.41% | +51.41% | +81.13% | 24.28B | |
| -3.08% | -5.94% | +103.97% | -46.17% | 22.46B | |
| +0.72% | +1.39% | -7.90% | +177.29% | 20.04B | |
| +1.13% | -5.67% | +65.36% | +120.26% | 16.14B | |
| Average | -0.41% | -0.45% | +30.53% | +51.30% | 37.03B | |
| Weighted average by Cap. | -0.33% | +1.06% | +23.37% | +41.05% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 8.65B 9.97B 8.1B 7.41B 13.99B 950B 14.17B 94.76B 37.19B 474B 37.43B 36.61B 1,579B | 9.7B 11.18B 9.08B 8.31B 15.68B 1,065B 15.89B 106B 41.7B 532B 41.97B 41.05B 1,771B |
| Net income | 1.87B 2.16B 1.75B 1.6B 3.03B 206B 3.07B 20.51B 8.05B 103B 8.1B 7.93B 342B | 2.34B 2.7B 2.19B 2.01B 3.79B 257B 3.84B 25.66B 10.07B 128B 10.13B 9.91B 428B |
| Net Debt | 228M 263M 214M 195M 369M 25.05B 374M 2.5B 981M 12.52B 987M 966M 41.66B | -1.94B -2.24B -1.82B -1.66B -3.14B -213B -3.18B -21.25B -8.34B -106B -8.39B -8.21B -354B |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
